Taysha Gene Therapies to Participate in Upcoming April Investor Healthcare Conferences

Taysha Gene Therapies (Nasdaq: TSHA) will participate in the Guggenheim Genomic Medicines and Rare Disease Day Conference on April 1, 2022, at 4:00 PM ET, and the 21st Annual Needham Virtual Healthcare Conference on April 11, 2022, at 11:45 AM ET.

Rhea-AI Impact

(Moderate)

Rhea-AI Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Tags

conferences

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

03/23/2022 - 07:00 AM EDT

Guggenheim Genomic Medicines and Rare Disease Conference on April 1, 2022 at 4:00 pm ET

21^st Annual Needham Virtual Healthcare Conference April 11, 2022 at 11:45 am ET

DALLAS--(BUSINESS WIRE)-- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced its participation in upcoming fireside chats at the Guggenheim Genomic Medicines and Rare Disease Day Conference and the 21^st Annual Needham Virtual Healthcare Conference.

Conference Details:
Event:		Guggenheim Genomic Medicines and Rare Disease Day Conference
Date:		April 1, 2022
Time:		4:00 pm ET
Format:		Fireside Chat
Participants:		RA Session II, President, Founder and CEO
		Dr. Suyash Prasad, Chief Medical Officer and Head of R&D
		Kamran Alam, Chief Financial Officer

Conference Details:
Event:		21^st Annual Needham Virtual Healthcare Conference
Date:		April 11, 2022
Time:		11:45 am ET
Format:		Fireside Chat
Participants:		RA Session II, President, Founder and CEO
		Dr. Suyash Prasad, Chief Medical Officer and Head of R&D
		Kamran Alam, Chief Financial Officer

About Taysha Gene Therapies

Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives. More information is available at www.tayshagtx.com.